Related Experiment Video
Updated: Jun 23, 2025

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal
Danyu Chen1, Fenfen Ji1, Qiming Zhou1
1Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Abstract:
The N6-methyladenosine (m6A) RNA-binding protein YTHDF1 is frequently overexpressed in colorectal cancer and drives chemotherapeutic resistance. To systematically identify druggable targets in colorectal cancer with high expression of YTHDF1, this study used a CRISPR/Cas9 screening strategy that revealed RUVBL1 and RUVBL2 as putative targets. RUVBL1/2 were overexpressed in primary colorectal cancer samples and represented independent predictors of poor patient prognosis. Functionally, loss of RUVBL1/2 preferentially impaired the growth of YTHDF1-high colorectal cancer cells, patient-derived primary colorectal cancer organoids, and subcutaneous xenografts. Mechanistically, YTHFD1 and RUVBL1/2 formed a positive feedforward circuit to accelerate oncogenic translation. YTHDF1 bound to m6A-modified RUVBL1/2 mRNA to promote translation initiation and protein expression. Coimmunoprecipitation and mass spectrometry identified that RUVBL1/2 reciprocally interacted with YTHDF1 at 40S translation initiation complexes. Consequently, RUVBL1/2 depletion stalled YTHDF1-driven oncogenic translation and nascent protein biosynthesis, leading to proliferative arrest and apoptosis. Ribosome sequencing revealed that RUVBL1/2 loss impaired the activation of MAPK, RAS, and PI3K-AKT signaling induced by YTHDF1. Finally, the blockade of RUVBL1/2 by the pharmacological inhibitor CB6644 or vesicle-like nanoparticle-encapsulated siRNAs preferentially arrested the growth of YTHDF1-expressing colorectal cancer in vitro and in vivo. Our findings show that RUVBL1/2 are potential prognostic markers and druggable targets that regulate protein translation in YTHDF1-high colorectal cancer. Significance: RUVBL1/2 inhibition is a therapeutic strategy to abrogate YTHDF1-driven oncogenic translation and overcome m6A dysregulation in colorectal cancer.
Insights
Overexpressed YTHDF1 in colorectal cancer drives resistance. Targeting RUVBL1/2 impairs YTHDF1-driven cancer growth by blocking oncogenic translation, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- N6-methyladenosine (m6A) RNA-binding protein YTHDF1 is overexpressed in colorectal cancer (CRC), contributing to chemotherapeutic resistance.
- Identifying novel therapeutic targets in YTHDF1-high CRC is crucial for improving patient outcomes.
Purpose of the Study:
- To identify druggable targets in YTHDF1-high colorectal cancer.
- To elucidate the functional and mechanistic roles of RUVBL1 and RUVBL2 in YTHDF1-driven CRC.
Main Methods:
- CRISPR/Cas9 screening to identify targets.
- Analysis of patient samples for RUVBL1/2 expression and prognostic value.
- Functional assays in cancer cells, organoids, and xenografts.
- Coimmunoprecipitation, mass spectrometry, and ribosome sequencing.
- Pharmacological inhibition and siRNA-mediated knockdown of RUVBL1/2.
Main Results:
- CRISPR screening identified RUVBL1 and RUVBL2 as putative targets in YTHDF1-high CRC.
- RUVBL1/2 are overexpressed in CRC and predict poor prognosis.
- Loss of RUVBL1/2 selectively inhibits the growth of YTHDF1-high CRC cells, organoids, and xenografts.
- YTHDF1 and RUVBL1/2 form a feedforward loop promoting oncogenic translation.
- RUVBL1/2 inhibition via CB6644 or siRNAs arrests YTHDF1-expressing CRC growth.
Conclusions:
- RUVBL1/2 are potential prognostic markers and druggable targets in YTHDF1-high colorectal cancer.
- Targeting RUVBL1/2 disrupts YTHDF1-driven oncogenic translation and protein synthesis.
- RUVBL1/2 inhibition represents a promising therapeutic strategy for YTHDF1-driven colorectal cancer.
More Related Videos
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
MicroRNAs
Inhibition of Cdk Activity
Leaky Scanning

